Serum GFAP as a biomarker for disease severity in multiple sclerosis

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Abstract While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) an...

Full description

Bibliographic Details
Main Authors: A. Abdelhak, A. Huss, J. Kassubek, H. Tumani, M. Otto
Format: Article
Language:English
Published: Nature Publishing Group 2018-10-01
Series:Scientific Reports
Subjects:
Serum GFAP
Glial Fibrillary Acidic Protein (GFAP)
Relapsing-remitting MS (RRMS)
GFAP Levels
Expanded Disability Status Scale (EDSS)
Online Access:https://doi.org/10.1038/s41598-018-33158-8

Similar Items

Similar Items